CoChat

Defining molecular glues with a dual-nanobody cannabidiol sensor

Open access

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index; 15 of the 40 sources its claims cite were checked for support.

Abstract

“Molecular glue” (MG) is a term coined to describe the mechanism of action of the plant hormone auxin and subsequently used to characterize synthetic small molecule protein degraders exemplified by immune-modulatory imide drugs (IMiDs). Prospective development of MGs, however, has been hampered by its elusive definition and thermodynamic characteristics. Here, we report the crystal structure of a dual-nanobody cannabidiol-sensing system, in which the ligand promotes protein-protein interaction in a manner analogous to auxin. Through quantitative analyses, we draw close parallels among the dual-nanobody cannabidiol sensor, the auxin perception complex, and the IMiDs-bound CRL4 CRBN E3, which can bind and ubiquitinate “neo-substrates”. All three systems, including the recruitment of IKZF1 and CK1α to CRBN, are characterized by the lack of ligand binding activity in at least one protein partner and an under-appreciated preexisting low micromolar affinity between the two proteinaceous subunits that is enhanced by the ligand to reach the nanomolar range. These two unifying features define MGs as a special class of proximity inducers distinct from bifunctional compounds and can be used as criteria to guide target selection for future rational discovery of MGs.

Overview

CoChat Summary

TL;DR

The paper reports the 2.0 Å crystal structure of a dual-nanobody cannabidiol sensor and uses quantitative biophysics to compare it with auxin and IMiD systems. It proposes that molecular glues are defined by no detectable ligand affinity to at least one protein partner plus a preexisting low-micromolar affinity between the two protein partners that the ligand enhances to the nanomolar range.

Key findings

  • The CA14-CBD-DB21 ternary complex was determined at 2.0 Å; CBD is buried at the nanobody interface, the complex buries ~1400 Ų with about two-thirds contributed by protein–protein interactions, and the channel is too narrow for CBD to enter or escape without nanobody dissociation.
  • In the CBD sensor, CA14 binds CBD with 2.2 μM affinity, DB21 shows no detectable CBD affinity, DB21 binds CBD-bound CA14 with Kd 43 nM, and ligand-free CA14-DB21 has ~20 μM affinity; CBD enhances the interaction ~450-fold. D34A in CA14 disables the response, while DB21 F48A/H101A mutations reduce enhancement to ~10-fold.
  • In the auxin system, TIR1 binds auxin with 13.4 μM affinity, Aux/IAA7 shows no detectable auxin affinity, TIR1-IAA7 affinity is 30.5 nM with auxin versus ~18–20 μM without auxin, giving ~600-fold enhancement.
  • For IMiDs, DDB1–CRBN has intrinsic affinity for IKZF1 at 200–300 nM, increased by pomalidomide to 50–70 nM, and for CK1α at 2.3 μM, increased by lenalidomide to 75 nM. The paper defines MGs by lack of detectable affinity to at least one partner plus quantifiable intrinsic protein–protein affinity, with positive cooperativity and a sigmoid dose-response lacking a hook effect.

Methods

  • Crystallized the CA14-CBD-DB21 ternary complex, collected X-ray data at 2.0 Å, and solved the structure by molecular replacement; nanobodies were expressed in E. coli periplasm, purified, and assembled with CBD.
  • Measured ligand binding by ITC and protein–protein affinities by BLI and AlphaScreen competition assays in the absence or presence of saturating MG; performed structure-guided mutagenesis of CA14 D34 and DB21 F48/H101.
  • Built a three-body equilibrium model for topologically trapped MGs, simulated dose-response curves using Kd1, Kd2, and protein concentrations, and validated predictions with AlphaScreen CBD and auxin dose-response experiments.

Limitations

  • Stated: CA14 remained refractory to crystallization, so the contribution of the CBD-DB21 interface was assessed by mutagenesis rather than direct apo/binary CA14 structures; the paper also notes the open question of what affinity range is amenable to diffusible MG compounds.
  • Evident: The proposed MG definition is derived from a small set of systems—an engineered CBD sensor, auxin, and IMiDs—and from in vitro binding assays; generalizability to all molecular glues and cellular contexts is not established by this study.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-022-28507-1

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Overall structure of a CBD-bound dual-nanobody sensor. a Chemical structures of cannabidiol (CBD) and tetrahydrocannabinol (THC). b Two orthogonal views of the crystal structure of the CA14-CBD-DB21 ternary complex. CBD is shown as green and red spheres. CA14 and DB21 are shown as cartoon diagrams and colored blue and orange, respectively. Three complementarity determining regions (CDRs) of CA14 and DB21 are highlighted in cyan and olive, respectively. CDR1, CDR2, and CDR3 are labeled as 1, 2, and 3. c Cross-section view of the CBD-binding pocket formed by the nanobody dimer. CBD, shown in green and red spheres, is located in the central pocket with a nearby channel too small for it to enter or escape.
Fig. 1 Overall structure of a CBD-bound dual-nanobody sensor. a Chemical structures of cannabidiol (CBD) and tetrahydrocannabinol (THC). b Two orthogonal views of the crystal structure of the CA14-CBD-DB21 ternary complex. CBD is shown as green and red spheres. CA14 and DB21 are shown as cartoon diagrams and colored blue and orange, respectively. Three complementarity determining regions (CDRs) of CA14 and DB21 are highlighted in cyan and olive, respectively. CDR1, CDR2, and CDR3 are labeled as 1, 2, and 3. c Cross-section view of the CBD-binding pocket formed by the nanobody dimer. CBD, shown in green and red spheres, is located in the central pocket with a nearby channel too small for it to enter or escape.CC BY · PubMed Central
Fig. 2 Intermolecular interfaces among CBD, CA14, and DB21. a, b Two orthogonal close-up views of the interface between CBD and CA14. CBD is shown in green and red sticks. CA14 is shown in dark blue surface representation except for three complementarity determining regions (CDRs) highlighted in cyan. c, d Two orthogonal close-up views of the interface between CBD and DB21. DB21 is shown in orange surface representation except for three CDRs highlighted in yellow. e, f Two close-up views of the interface between CA14 and DB21 with CBD sandwiched in the middle. A CDR and its nearby region of a nanobody (shown in cartoon model) directly pack against their equivalent parts in the other nanobody (shown in surface representation).
Fig. 2 Intermolecular interfaces among CBD, CA14, and DB21. a, b Two orthogonal close-up views of the interface between CBD and CA14. CBD is shown in green and red sticks. CA14 is shown in dark blue surface representation except for three complementarity determining regions (CDRs) highlighted in cyan. c, d Two orthogonal close-up views of the interface between CBD and DB21. DB21 is shown in orange surface representation except for three CDRs highlighted in yellow. e, f Two close-up views of the interface between CA14 and DB21 with CBD sandwiched in the middle. A CDR and its nearby region of a nanobody (shown in cartoon model) directly pack against their equivalent parts in the other nanobody (shown in surface representation).CC BY · PubMed Central
Fig. 3 Quantitative analysis of CBD dual-nanobody sensor. a, b CBD binding to CA14 and DB21 measured by isothermal titration calorimetry (ITC). Source data are provided as a Source Data file. c, e BioLayer interferometry (BLI) measurements of CA14 and DB21 interaction in the presence and absence of CBD at a saturating concentration. Black lines represent the kinetics of association and dissociation of CA14 with biotinylated DB21 immobilized on the probe. Red lines represent curve fitting at the initial phase of association and dissociation. For CA14–DB21 interaction without CBD, there was a discrepancy between the Kd values determined by kinetics (3.0 ± 0.8 μM) and equilibrium measurements. The latter is consistent with the result obtained in AlphaScreen assays. Kd, dissociation constant. Source data are provided as a Source Data file. d, f AlphaScreen competition assays for assessing DB21 binding to CA14 with and without CBD. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file.
Fig. 3 Quantitative analysis of CBD dual-nanobody sensor. a, b CBD binding to CA14 and DB21 measured by isothermal titration calorimetry (ITC). Source data are provided as a Source Data file. c, e BioLayer interferometry (BLI) measurements of CA14 and DB21 interaction in the presence and absence of CBD at a saturating concentration. Black lines represent the kinetics of association and dissociation of CA14 with biotinylated DB21 immobilized on the probe. Red lines represent curve fitting at the initial phase of association and dissociation. For CA14–DB21 interaction without CBD, there was a discrepancy between the Kd values determined by kinetics (3.0 ± 0.8 μM) and equilibrium measurements. The latter is consistent with the result obtained in AlphaScreen assays. Kd, dissociation constant. Source data are provided as a Source Data file. d, f AlphaScreen competition assays for assessing DB21 binding to CA14 with and without CBD. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Mutational analysis of CBD dual-nanobody sensor. a A close-up stereo view of CA14 and DB21 residues interacting with CBD (green and red sticks) with its positive Fo − Fc electron density contoured at 1σ (purple mesh). CA14 (blue) and DB21 (orange) residues are shown in the stick model. The hydrogen bond between CA14 Asp34 and CBD are represented by cyan dashes. b AlphaScreen competition assays for assessing the effect of D34A mutation in CA14 (WT CA14 in brown and CA14 D34A mutant in blue) on ternary complex formation with CBD at a saturating concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file. c–e BLI analyses for assessing the effects of H101A, F48A, and F48A-H101A mutations in DB21 on ternary complex formation with CBD at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. Source data are provided as a Source Data file. f, g AlphaScreen competition assays for assessing the effects of F48A (red) and F48A-H101A (green) mutations on CA14–DB21 interaction in the presence or absence of CBD at a saturating concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file.
Fig. 4 Mutational analysis of CBD dual-nanobody sensor. a A close-up stereo view of CA14 and DB21 residues interacting with CBD (green and red sticks) with its positive Fo − Fc electron density contoured at 1σ (purple mesh). CA14 (blue) and DB21 (orange) residues are shown in the stick model. The hydrogen bond between CA14 Asp34 and CBD are represented by cyan dashes. b AlphaScreen competition assays for assessing the effect of D34A mutation in CA14 (WT CA14 in brown and CA14 D34A mutant in blue) on ternary complex formation with CBD at a saturating concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file. c–e BLI analyses for assessing the effects of H101A, F48A, and F48A-H101A mutations in DB21 on ternary complex formation with CBD at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. Source data are provided as a Source Data file. f, g AlphaScreen competition assays for assessing the effects of F48A (red) and F48A-H101A (green) mutations on CA14–DB21 interaction in the presence or absence of CBD at a saturating concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. IC50, half-maximum inhibitory concentration. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Quantitative analysis of the auxin-sensing system. a, b Auxin binding to TIR1 and Aux/IAA7 peptide measured by ITC experiments. ND not detected. Source data are provided as a Source Data file. c, d BLI and AlphaScreen competition assays for assessing the affinity of Aux/IAA7 to TIR1 in the presence of auxin at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. e, f BLI and AlphaScreen competition assays for assessing the intrinsic affinity of Aux/IAA7 to TIR1. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 4 biologically independent samples. Source data are provided as a Source Data file.
Fig. 5 Quantitative analysis of the auxin-sensing system. a, b Auxin binding to TIR1 and Aux/IAA7 peptide measured by ITC experiments. ND not detected. Source data are provided as a Source Data file. c, d BLI and AlphaScreen competition assays for assessing the affinity of Aux/IAA7 to TIR1 in the presence of auxin at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. e, f BLI and AlphaScreen competition assays for assessing the intrinsic affinity of Aux/IAA7 to TIR1. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 4 biologically independent samples. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Quantitative analysis of IMiDs system. a, b BLI and AlphaScreen competition assays for assessing the intrinsic affinity of IKZF1 (ZF2-3) to DDB1–CRBN. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. c, d BLI and AlphaScreen competition assays for assessing the affinity of IKZF1 (ZF2-3) to DDB1–CRBN in the presence of pomalidomide at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. e, f BLI measurements of CK1a and DDB1–CRBN interaction in the absence and presence of lenalidomide at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. Source data are provided as a Source Data file.
Fig. 6 Quantitative analysis of IMiDs system. a, b BLI and AlphaScreen competition assays for assessing the intrinsic affinity of IKZF1 (ZF2-3) to DDB1–CRBN. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. c, d BLI and AlphaScreen competition assays for assessing the affinity of IKZF1 (ZF2-3) to DDB1–CRBN in the presence of pomalidomide at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. IC50, half-maximum inhibitory concentration. Data were presented as mean ± s.d. of n = 3 biologically independent samples. Source data are provided as a Source Data file. e, f BLI measurements of CK1a and DDB1–CRBN interaction in the absence and presence of lenalidomide at a saturating concentration. Red lines represent curve fitting at the initial phase of association and dissociation. Kd, dissociation constant. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Mathematical simulation of MG system. a, b Topology and equilibria of a general and topologically trapped MG system. For the topologically trapped MG system, MG (orange) is buried at the protein interface and cannot enter its binding site if the binary protein complex between the Receptor (green) and the dimerization partner (blue) is formed first. R receptor, D dimerization partner, R•MG the receptor-MG binary complex, R•D the binary complex of receptor-dimerization partner, and R•MG•D the ternary complex of receptor-MG-dimerization partner. Four equilibrium dissociation constants, Kd1 (R,MG), Kd2 (R•MG,D), Kd3 (R,D), and Kd4 (R•D,MG), represent the affinity between R and MG, R•MG and D, R and D, and R•D and MG, respectively. c MG dose-response curve calculated by a mathematical model. d, e Experimentally detected MG dose-response curve for CBD and auxin, respectively. Data were presented as mean ± s.d. of n = 3 biologically independent samples. EC50, half-maximum response concentration. Source data are provided as a Source Data file. f Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd1 and variable Kd2. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd2 value. g Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd2 and variable Kd1. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd1 value. h, i Simulation of CBD dose-response curve with variable total protein concentrations [CA14] and [DB21]. Ternary complex (%) represents [CA14•CBD•DB21]/[CA14•CBD•DB21]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing identical [CA14] and [DB21] value. j, k Simulation of auxin dose-response curve with fixed total [TIR1] and variable [IAA7]. Ternary complex (%) represents [TIR1•auxin•IAA7]/[TIR1•auxin•IAA7]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing [IAA7] value.
Fig. 7 Mathematical simulation of MG system. a, b Topology and equilibria of a general and topologically trapped MG system. For the topologically trapped MG system, MG (orange) is buried at the protein interface and cannot enter its binding site if the binary protein complex between the Receptor (green) and the dimerization partner (blue) is formed first. R receptor, D dimerization partner, R•MG the receptor-MG binary complex, R•D the binary complex of receptor-dimerization partner, and R•MG•D the ternary complex of receptor-MG-dimerization partner. Four equilibrium dissociation constants, Kd1 (R,MG), Kd2 (R•MG,D), Kd3 (R,D), and Kd4 (R•D,MG), represent the affinity between R and MG, R•MG and D, R and D, and R•D and MG, respectively. c MG dose-response curve calculated by a mathematical model. d, e Experimentally detected MG dose-response curve for CBD and auxin, respectively. Data were presented as mean ± s.d. of n = 3 biologically independent samples. EC50, half-maximum response concentration. Source data are provided as a Source Data file. f Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd1 and variable Kd2. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd2 value. g Simulation of MG dose-response curve with fixed total protein concentrations [R], [D], and Kd2 and variable Kd1. Blue, red, green, and purple lines indicate dose-response curves with an increasing Kd1 value. h, i Simulation of CBD dose-response curve with variable total protein concentrations [CA14] and [DB21]. Ternary complex (%) represents [CA14•CBD•DB21]/[CA14•CBD•DB21]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing identical [CA14] and [DB21] value. j, k Simulation of auxin dose-response curve with fixed total [TIR1] and variable [IAA7]. Ternary complex (%) represents [TIR1•auxin•IAA7]/[TIR1•auxin•IAA7]MAX. Blue, red, green, and purple lines indicate dose-response curves with a decreasing [IAA7] value.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 8 Not checked · 74 Own results and interpretations

49 more claims

Create a free account to see all 89 claims and to verify the 25 references still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 58 references

Cited by

See all 131

Metadata

Authors
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N.
Affiliations
  • Howard Hughes Medical Institute (US)
  • University of Washington (US)
Corresponding author
Zheng, Ning
Venue
Nature Communications
Published
2022-02-10
Volume
13
Issue
1
Pages
815-815
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4211187930
Cited by
125
References
59
Citations by year
2026: 25 · 2025: 40 · 2024: 28 · 2023: 21 · 2022: 11
FWCI
8.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Howard Hughes Medical Institute
  • U.S. Department of Health & Human Services | National Institutes of Health (1R35GM128918, R21DA051555, R21DA051194)
  • University of Washington Innovation Award
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
Keywords
molecular glues, cannabidiol, auxin perception, protein-protein interaction, cereblon, CRL4 E3 ubiquitin ligase, IKZF1, CK1α, protein degraders, crystal structure
MeSH terms
Lenalidomide, Adhesives, Cannabidiol, Indoleacetic Acids, Models, Molecular, Protein Binding, Substrate Specificity, Casein Kinase Ialpha, Nanostructures, Ikaros Transcription Factor, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining molecular glues with a dual-nanobody cannabidiol sensor. https://app.cochat.ai/papers/10.1038/s41467-022-28507-1
The paper
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022). Defining molecular glues with a dual-nanobody cannabidiol sensor. Nature Communications. https://doi.org/10.1038/s41467-022-28507-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.